Avidity Biosciences, Inc. Common Stock
RNAAvidity Biosciences, Inc. is a biotechnology company focused on developing targeted RNA therapies using antibody-oligonucleotide conjugates. Their innovation aims to treat muscle and other diseases by delivering RNA-based therapeutics directly to specific tissues, leveraging their proprietary AOCs platform for precise and effective treatment options.
Company News
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies involving mergers and acquisitions.
Novartis anticipates 5-6% annual sales growth from 2025-2030, raised peak sales projections for key drugs like Kisqali and Scemblix, and expects to maintain operating margins above 40% while planning significant U.S. infrastructure expansion.
Novartis reported Q3 2025 results with net sales rising 8% to $13.91 billion, driven by strong performance in key growth drugs like Kisqali and Kesimpta. The company reaffirmed its full-year guidance despite generic competition and announced a $12 billion acquisition of Avidity Biosciences.
Dyne Therapeutics stock surged over 41% after Novartis announced a $12 billion acquisition of Avidity Biosciences, a peer biotech company developing similar muscle disorder therapies using antibody-based treatments.
Novartis will acquire Avidity Biosciences for $12 billion, focusing on its neuroscience pipeline and RNA-targeting platform, with shareholders receiving $72 per share and early-stage cardiology programs being spun off into a separate public company.
